TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$12.75 | -$1.83 | Beat |
| May 13, 2026 | -$12.75 | -$0.46 | Beat |
| Feb 25, 2026 | -$12.75 | -$1.04 | Beat |
| Nov 14, 2025 | – | -$1.56 | |
| Aug 15, 2025 | – | -$11.26 | |
| May 15, 2025 | – | $0.12 |